Oncology & Cancer

Targeting gene mutations to treat ovarian cancers

New research has shown that ovarian cancer patients with a tumour mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

Surgery

V600E BRAF mutation tied to worse survival in CRC liver mets

(HealthDay)—For patients undergoing resection of colorectal liver metastases (CRLM), the presence of the V600E BRAF mutation is associated with worse prognosis, according to a study published online May 16 in JAMA Surgery.

Oncology & Cancer

Melanoma cells rewire to resist drug treatment

In 2014, new combination therapies to treat patients with metastatic melanoma hit the market, helping extend the lives of those with this aggressive disease. Yet unfortunately, after several months of treatment, almost all ...

Oncology & Cancer

A Braf kinase-inactive mutant induces lung adenocarcinoma

The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, complicating the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious ...

page 2 from 10